skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
PADRE-CMV Fusion Peptide Vaccine (Code C78820)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: PADRE-CMV Fusion Peptide Vaccine

Definition: A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope.

Display Name: PADRE-CMV Fusion Peptide Vaccine

Label: PADRE-CMV Fusion Peptide Vaccine

NCI Thesaurus Code: C78820 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL387731  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
PADRE-CMV Fusion Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 601195
PDQ Open Trial Search ID 601195 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C78820
Contributing_Source CTRP
Legacy_Concept_Name PADRE-CMV_Fusion_Peptide_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom